JCR Pharmaceuticals Co., Ltd. (TYO:4552)

JCR Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, JCR Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of ¥707. The average 1-year stock price forecast is 41.62% higher than the current stock price, while the lowest is ¥500 (+0.20%) and the highest is ¥1,200 (+140.48%).

Price Target: ¥707 (+41.62%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	¥500	¥707	¥550	¥1,200
Change	+0.20%	+41.62%	+10.22%	+140.48%

* Price targets were last updated on Oct 9, 2026.

Analyst Ratings

The average analyst rating for JCR Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Oct '26	Nov '26
Strong Buy	1	1	1	1	2	2
Buy	0	0	0	0	0	0
Hold	5	5	5	5	4	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst Mizuho Securities No rating	Mizuho Securities	Buy Maintains ¥1,200	Buy	Maintains	¥1,200	+140.48%	Oct 9, 2026
Unknown Analyst Citi No rating	Citi	Hold Maintains ¥560	Hold	Maintains	¥560	+12.22%	Aug 27, 2026
Unknown Analyst Nomura No rating	Nomura	Hold Maintains ¥430 → ¥540	Hold	Maintains	¥430 → ¥540	+8.22%	Aug 18, 2026
Unknown Analyst Daiwa No rating	Daiwa	Hold Maintains ¥540	Hold	Maintains	¥540	+8.22%	Jun 25, 2026
Unknown Analyst Morgan Stanley No rating	Morgan Stanley	Hold Maintains ¥500	Hold	Maintains	¥500	+0.20%	Jun 9, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

45.52B

Increased by 12.91%

from 40.32B

Revenue Next Year

42.96B

Decreased by -5.64%

from 45.52B

EPS This Year

2.01

Decreased by -88.76%

from 17.86

EPS Next Year

3.61

Increased by 79.68%

from 2.01

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	51.08B	34.34B	42.87B	33.07B	40.32B	45.52B
Revenue Growth	69.79%	-32.77%	24.83%	-22.86%	21.91%	12.91%
Gross Profit	40.62B	25.46B	31.25B	22.17B	30.19B	34.70B
Gross Margin	79.52%	74.13%	72.90%	67.04%	74.87%	76.23%
Operating Income	19.94B	4.98B	7.53B	-6.41B	431.00M	911.90M
Net Income	14.51B	3.77B	5.51B	-4.46B	2.18B	244.20M
EPS	116.80	30.22	43.92	-36.02	17.86	2.01
EPS Growth	110.34%	-74.13%	45.33%	-	-	-88.76%
Forward PE	25.23	25.97	15.47	18.68	39.18	248.51
Dividend / Share	20.00	20.00	20.00	20.00	20.00	20.00
Dividend Growth	73.91%	-	-	-	-	-
Free Cash Flow	-	-	-	-	-12.64B	-7.68B
No. Analysts	-	-	-	-	-	6

Financial currency is JPY.

Revenue Forecast

Chart

Revenue	2027	2028	2029
High	46.2B
Avg	45.5B
Low	44.7B

Revenue Growth

Chart

Revenue Growth	2027	2028	2029
High	14.7%
Avg	12.9%
Low	10.9%

EPS Forecast

Chart

EPS	2027	2028	2029
High	3.38
Avg	2.01
Low	0.82

EPS Growth

EPS Growth	2027	2028	2029
High	-81.1%
Avg	-88.8%
Low	-95.4%

Data Sources: S&P Global Market Intelligence and TipRanks Last updated: Oct 9, 2026

Price targets, consensus ratings and financial forecasts are provided by S&P Global Market Intelligence. Individual analyst data is provided by TipRanks. Price targets and consensus ratings update every hour to every three days, while individual analyst data updates in near real-time.

Data Sources Report a data error